Malignant peritoneal neoplasm – Diagnostics – Overview of Information and Clinical Research

Malignant peritoneal neoplasm is a rare and serious cancer affecting the peritoneum, the thin tissue lining the abdominal cavity. Because symptoms often appear only when the disease has advanced, most people are diagnosed at a later stage, making early and accurate testing crucial for planning the best possible care.

Introduction: Who Should Undergo Diagnostics

Diagnosing malignant peritoneal neoplasm can be challenging because the disease often develops quietly without clear early warning signs. People who should consider seeking diagnostic evaluation include those experiencing persistent abdominal symptoms that don’t improve over time. If you notice ongoing belly swelling or bloating, especially if it seems like you’re gaining weight around your middle despite no changes in your diet or exercise habits, it’s worth discussing with a doctor.^[1]

Women who have already been treated for ovarian cancer or who carry genetic changes such as BRCA1 or BRCA2 mutations (alterations in genes that normally help prevent cancer) should be especially attentive to new symptoms. These individuals face higher risks and may benefit from more proactive monitoring. Similarly, people with a family history of peritoneal, ovarian, or fallopian tube cancers should inform their healthcare provider, as this can influence the decision to pursue diagnostic testing.^[1]

It’s advisable to seek medical attention if you experience a combination of symptoms such as abdominal discomfort or pain, a feeling of fullness even after eating small amounts, changes in bowel habits like constipation, unexplained weight loss or gain, frequent urination, or persistent fatigue. These symptoms can be vague and may resemble other less serious conditions, but when they persist or worsen, they warrant thorough investigation.^[2]^[4]

People who have been diagnosed with cancers in nearby organs, such as the colon, stomach, appendix, or ovaries, should also be aware that cancer can spread to the peritoneum. In such cases, doctors may recommend diagnostic tests to check whether the cancer has extended beyond its original location. This is particularly important because early detection of peritoneal involvement can change treatment plans and potentially improve outcomes.^[2]

⚠️ Important

Many symptoms of peritoneal cancer are vague and can be mistaken for digestive problems or other common conditions. Don’t ignore persistent or worsening symptoms, especially if you have risk factors like a family history of cancer or genetic mutations. Early consultation with a healthcare provider can make a significant difference in diagnosis and treatment planning.

Classic Diagnostic Methods

Identifying malignant peritoneal neoplasm requires a combination of approaches because the disease often spreads across the abdominal lining without forming easily visible masses. The diagnostic process typically begins with a detailed conversation between you and your doctor about your symptoms, medical history, and any family history of cancer. This initial step helps the healthcare team understand your risk profile and guides them toward the most appropriate tests.^[2]

Physical Examination

After discussing your symptoms, your doctor will perform a physical examination. This involves feeling your abdomen to check for any unusual lumps, masses, or areas of tenderness. In some cases, the doctor can detect the presence of ascites, which is fluid buildup in the abdominal cavity, by noticing swelling or a feeling of fullness in your belly. If you’re a woman, a pelvic exam may also be performed to check for abnormalities in the uterus, vagina, ovaries, fallopian tubes, bladder, and rectum.^[2]^[8]

Blood Tests and Tumor Markers

Blood tests play an important role in the diagnostic process. One commonly used test measures CA-125, a substance that can be found at higher levels in the blood of people with peritoneal or ovarian cancer. However, it’s important to understand that CA-125 levels can also be elevated for reasons unrelated to cancer, such as inflammation or other benign conditions. This means that while a high CA-125 reading can suggest the possibility of peritoneal cancer, it cannot confirm the diagnosis on its own. Your doctor will interpret these results alongside other findings.^[7]^[8]

In addition to CA-125, doctors may check for other tumor markers, which are chemicals produced by cancer cells. These blood tests can provide helpful clues, especially when trying to determine whether cancer has spread to the peritoneum from another organ.^[2]

Imaging Studies

Imaging tests are among the most valuable tools for detecting peritoneal cancer. A CT scan (computed tomography) of the abdomen and pelvis is often the first imaging test ordered. This test uses X-rays and a computer to create detailed cross-sectional images of the inside of your body, allowing doctors to see the extent of disease in the abdominal cavity. CT scans can reveal visible tumor spread, fluid buildup, and whether nearby organs are affected. However, CT scans are not always sensitive enough to detect very small cancers or early peritoneal disease, so a negative scan does not completely rule out the condition.^[2]^[9]

An MRI (magnetic resonance imaging) may also be used, particularly when doctors need more detailed images of soft tissues. MRI uses magnets and radio waves to create pictures of the inside of your body. The sensitivity of MRI depends on the size of the peritoneal implants; for larger tumors (greater than 10 millimeters), MRI can be as effective as CT in detecting disease.^[2]

Some centers may use PET-CT scans, which combine a PET scan (positron emission tomography) with a CT scan. This type of imaging can sometimes detect areas of active cancer that other scans might miss. However, whether PET-CT is better than standard CT for diagnosing peritoneal cancer is still a topic of debate, and it may not be routinely used in all cases.^[2]

Ultrasound

An ultrasound uses high-frequency sound waves to create images of structures inside your body. For peritoneal cancer, ultrasound has limited usefulness because it is not as sensitive or specific as CT or MRI. It may be used in certain situations, such as during a pelvic exam, but it generally plays only a minor role in diagnosing this disease.^[2]^[8]

Fluid Sampling and Biopsy

If imaging suggests the presence of peritoneal cancer, doctors may need to obtain a sample of tissue or fluid to confirm the diagnosis. One way to do this is through paracentesis, a procedure in which a needle is inserted into the abdomen to withdraw some of the fluid that has accumulated. This fluid is then examined under a microscope to look for cancer cells. A positive result strongly indicates that cancer is present in the peritoneum.^[9]

A biopsy involves removing a small piece of tissue from a suspected tumor and testing it in a laboratory. This can be done in several ways. In some cases, a needle biopsy may be performed with the guidance of imaging technology. In other cases, a surgical procedure may be needed to obtain the tissue sample.^[2]

Laparoscopy

Staging laparoscopy is a minimally invasive surgical procedure that allows doctors to look directly inside your abdominal cavity using a small camera inserted through a tiny incision. This procedure is especially valuable for finding peritoneal tumors that are too small to be seen on imaging scans. During laparoscopy, the surgeon can inspect the peritoneum, identify hidden tumors, and take tissue or fluid samples for testing. This procedure is considered safe and provides critical information for planning treatment.^[9]

⚠️ Important

Because peritoneal cancer often spreads without forming distinct masses, no single test can definitively diagnose the condition on its own. Doctors typically rely on a combination of imaging, blood tests, fluid analysis, and sometimes direct visualization through surgery to confirm the presence of cancer and determine how far it has spread.

Advanced Blood Tests

Newer technologies are being explored to improve the detection of peritoneal cancer. One such test is circulating tumor DNA (ctDNA), which looks for small fragments of DNA released by cancer cells into the bloodstream. This blood test can sometimes detect cancer that doesn’t show up on imaging scans. However, ctDNA testing is still relatively new and may not yet be widely available in all healthcare settings.^[9]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to manage peritoneal cancer. If you are considering participating in a clinical trial, you will need to undergo specific diagnostic tests to determine whether you are eligible. These tests ensure that the trial is appropriate for your particular stage and type of disease, and they help researchers collect consistent data across all participants.

Imaging and Tumor Burden Assessment

Most clinical trials require detailed imaging studies, such as CT or MRI scans, to assess the extent of cancer in your abdomen. Researchers need to know how much tumor is present and where it is located. One tool commonly used in clinical trials is the Peritoneal Carcinomatosis Index (PCI), which is a scoring system that maps the location and size of tumors throughout the peritoneum and small intestine. The PCI assigns a numerical score based on tumor distribution, and this score helps doctors determine whether a patient is a good candidate for certain treatments, such as surgery combined with chemotherapy.^[11]^[21]

Trials testing new surgical techniques or chemotherapy methods often require that the tumor burden be within a certain range. For example, some studies may only enroll patients whose tumors are considered resectable, meaning they can potentially be removed through surgery. Others may focus on patients with more advanced disease. The PCI score helps researchers and doctors communicate clearly about a patient’s eligibility.^[11]

Tissue Sampling and Histopathology

Before enrolling in a clinical trial, you may need to provide a tissue sample from your tumor so that researchers can analyze its characteristics. This is often done through a biopsy or during a laparoscopy procedure. The tissue is examined under a microscope to determine the type of cancer cells present, their appearance, and other features that can affect how the cancer behaves and responds to treatment. This process is called histopathology.^[2]^[13]

In some trials, researchers may also perform additional tests on the tissue, such as checking for specific genetic mutations or protein markers. These tests help identify patients who are most likely to benefit from targeted therapies, which are treatments designed to attack cancer cells with specific characteristics.^[3]

Blood Tests and Biomarkers

Clinical trials often include blood tests to measure tumor markers, such as CA-125, before treatment begins. Researchers track these markers over time to see how well a treatment is working. If you join a trial, you may need to have blood drawn at regular intervals to monitor changes in marker levels. Additionally, some trials may require testing for genetic mutations, such as BRCA1 or BRCA2, which can influence treatment decisions.^[1]

Performance Status and Overall Health

In addition to disease-specific tests, clinical trials assess your overall health and ability to tolerate treatment. Doctors use a measure called performance status, which evaluates how well you can carry out daily activities. This helps ensure that participants are healthy enough to undergo the treatments being studied. You may also need to have tests such as blood counts, kidney function tests, and heart function assessments to confirm that your organs are functioning well enough to handle the trial’s therapies.^[12]^[13]

Exclusion Criteria and Additional Testing

Many clinical trials have strict eligibility criteria, including exclusion rules. For example, some trials may not accept patients whose cancer has spread beyond the peritoneum to distant organs. Others may exclude individuals who have already received certain types of treatment. Diagnostic tests help researchers determine whether these criteria are met. Additional imaging, such as chest X-rays or scans of other body parts, may be required to confirm that cancer has not spread outside the abdominal cavity.^[12]

Participating in a clinical trial can give you access to new treatments that are not yet widely available. However, the diagnostic process for trial enrollment is thorough and may require more tests than standard care. Your healthcare team will guide you through these steps and help you understand what each test means for your eligibility and treatment options.

Prognosis and Survival Rate

Prognosis

The outlook for people with malignant peritoneal neoplasm depends on several factors, including the stage of cancer when it is diagnosed, the type of cells involved, and the patient’s overall health. Unfortunately, because symptoms often don’t appear until the disease has progressed, most people are diagnosed at a later stage, which generally means a more serious prognosis.^[1]

For primary peritoneal cancer, the prognosis is generally worse than for ovarian cancer, even though the two diseases are very similar. People diagnosed with peritoneal cancer also tend to be older than those diagnosed with ovarian cancer, which can influence treatment options and outcomes.^[1]

When peritoneal cancer is secondary, meaning it has spread from another organ such as the colon, stomach, or ovaries, the outlook depends largely on the characteristics of the original cancer. For example, peritoneal spread from colorectal or gastric cancers is typically considered advanced-stage disease, which often indicates a more challenging prognosis.^[2]

Treatment approaches can influence the prognosis significantly. Advances in surgical techniques, particularly a combination of cytoreductive surgery (removing as much visible tumor as possible) and hyperthermic intraperitoneal chemotherapy (HIPEC), have improved survival times for some patients. While traditional treatments offered median survival times ranging from four to twelve months, the use of multimodal therapy has shown promising results, with some patients experiencing survival approaching sixty months.^[12]^[13]

Factors that can affect prognosis include the extent of tumor spread within the abdomen, whether all visible cancer can be surgically removed, the patient’s performance status (their ability to carry out daily activities), and how well the cancer responds to chemotherapy. Patients who are candidates for complete surgical removal of tumors generally have better outcomes than those with unresectable disease.^[12]^[21]

Survival rate

Specific survival statistics for malignant peritoneal neoplasm vary widely depending on whether the cancer is primary or secondary, and on the treatment received. For traditional therapies, median survival has historically ranged from four to twelve months. However, with the introduction of advanced treatments such as cytoreductive surgery combined with HIPEC, median survival has increased significantly, with some studies reporting survival times approaching sixty months for carefully selected patients.^[12]^[13]

For malignant peritoneal mesothelioma, a specific subtype of peritoneal cancer, outcomes have also improved with multimodal therapy. While the disease remains serious, patients who undergo complete cytoreduction and HIPEC may experience better outcomes than those treated with chemotherapy alone.^[13]

It’s important to remember that survival statistics are based on large groups of people and cannot predict what will happen to any individual patient. Every person’s situation is unique, and factors such as overall health, age, response to treatment, and access to specialized care can all influence outcomes. Discussing your specific prognosis with your healthcare team can help you understand what to expect and make informed decisions about your care.^[1]

#1 Clinical Trials Search in Europe